This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Leads as US Plans Kids' COVID Vaccination in June
by Zacks Equity Research
The FDA accepts the EUA request from Pfizer (PFE) for its COVID-19 vaccine for use in kids below 5 years of age. The U.S. government plans to start vaccinating these kids in June, following an FDA panel advisory.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $52.68 in the latest trading session, marking a +0.59% move from the prior day.
Pfizer (PFE) Up 5.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
by Zacks Equity Research
GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer
by Zacks Equity Research
AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
by Zacks Equity Research
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
by Kinjel Shah
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
Pfizer (PFE) Reports More Positive Data From Etrasimod Study
by Zacks Equity Research
Pfizer (PFE) states that data from the ELEVATE 12 and ELEVATE 52 studies will form the basis of the regulatory submissions on etrasimod expected later this year
AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot
by Zacks Equity Research
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
by Zacks Equity Research
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA
by Zacks Equity Research
The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.
Pfizer & BioNTech COVID Jab Booster Effective in Kids Under 5
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide
by Kinjel Shah
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
by Zacks Equity Research
While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?
by Zacks Equity Research
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal
by Zacks Equity Research
Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.
The Zacks Analyst Blog Highlights NVIDIA, The Home Depot, Pfizer, The Walt Disney, and Salesforce
by Zacks Equity Research
NVIDIA, The Home Depot, Pfizer, The Walt Disney, and Salesforce are part of Zacks top Analyst Blog
Top Analyst Reports for NVIDIA, Home Depot, Pfizer & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), The Home Depot, Inc. (HD), and Pfizer Inc. (PFE).
Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update
by Kinjel Shah
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
Lilly's (LLY) Olumiant Gets Full Approval From FDA for COVID
by Zacks Equity Research
The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.
Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider
by Zacks Equity Research
Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.